Lung cancer, a new challenge in the HIV-infected population

Lavolé, A.; Wislez, Marie; Antoine, Martine; Mayaud, C; Milleron, B.; Cadranel, Jacquès

doi:10.1016/j.lungcan.2005.09.001

Cited by 45 publications

(50 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown an increased incidence of LC in PLWHIV when compared to the general population [5,7,8,9,10,11,12], even after the establishment of effective cART (table 1) [13,14,15,16,17,18]. A study from the UK that included 8,400 PLWHIV with LC diagnosed between 1986 and 2001 reported a 6.7-fold (95% confidence interval (CI) 3.1-13.9) increased risk of LC in the cART era as compared to pre-cART prior to 1996 (0.8, 95% CI 0.2-3.2) [19].…”

Section: Epidemiologymentioning

confidence: 99%

“…Even though pre-cART data suggested poorer prognosis for PLWHIV with LC [52,53,54,55], studies focusing in the post-cART era after 1996 found no significant differences in survival rates for PLWHIV [8,43,44,47,56]. The improved outcome is most likely related, in part, to the better overall health of PLWHIV, but also to the better care since having overcome several uncertainties and worries of the first years of the HIV epidemic.…”

Section: Clinical Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

HIV-Associated Lung Cancer

2017

View full text Add to dashboard Cite

Lung cancer (LC) is one of the most common non-AIDS (acquired immune deficiency syndrome)-defining malignancies. It occurs more frequently in persons living with human immunodeficiency virus (PLWHIV) than in the HIV-negative population. Compared to their HIV-negative counterparts, patients are usually younger and diagnosed at more advanced stages. The pathogenesis of LC in PLWHIV is not fully understood, but immunosuppression in combination with chronic infection and the oncogenic effects of smoking and HIV itself all seem to play a role. Currently, no established preventive screening is available, making smoking cessation the most promising preventive measure. Treatment protocols and standards are the same as for the general population. Notably, immuno-oncology will also become standard of care in a significant subset of HIV-infected patients with LC. As drug interactions and hematological toxicity must be taken into account, a multidisciplinary approach should include a physician experienced in the treatment of HIV. Only limited data is available on novel targeted therapies and checkpoint inhibitors in the setting of HIV.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Clinical Characteristicsmentioning

confidence: 99%

HIV-Associated Lung Cancer

2017

View full text Add to dashboard Cite

show abstract

“…The epidemiologic data are mixed in regard to CD41 cell count and risk for lung cancer; most individual studies have had limited power to assess relationships between cancer and HIV disease markers. Some studies have not demonstrated an association of AIDS diagnoses or CD41 cell counts with lung cancer risk, arguing against a major effect of immunosuppression (18,32,33,41,49). However, several other studies have reported increased lung cancer risk among HIV-infected persons with advanced immune suppression, evaluated as a prior AIDS diagnosis or lower CD41 cell counts compared with those HIV-infected persons with relatively intact immune function (4,22,32).…”

Section: Role Of Immunosuppression Hiv Viral Load and Artmentioning

confidence: 99%

HIV Infection in the Etiology of Lung Cancer: Confounding, Causality, and Consequences

Kirk

Merlo²

2011

Proceedings of the American Thoracic Society

View full text Add to dashboard Cite

“…Today, one-third of HIV-infected patients die of malignancies, and the NADC type causing the most deaths among these patients is lung cancer [1]. In general, advanced lung cancer patients with HIV infection have been considered to have a poor prognosis, with a life expectancy of 5 months in contrast to more than 12 months among non-HIV cases [2]. The benefit of intensive treatment has been uncertain in this setting because of the poor bone marrow reserve and perceived fragility of the HIV population.…”

Section: Introductionmentioning

confidence: 99%

Concomitant Chemoradiotherapy and Antiretroviral Therapy for HIV-Infected Patients with Locoregionally Advanced Non-Small Cell Lung Cancer: Benefit and Tolerability of Treatment in 2 Cases

Okuma

Yanagisawa²,

Hosomi³

et al. 2013

Oncol Res Treat

View full text Add to dashboard Cite

Background: Human immunodeficiency virus (HIV)-infected patients are surviving longer since the advent of antiretroviral therapy. Therefore, more patients are developing non-AIDS-defining cancers which increasingly determine mortality. Case Reports: Here we present 2 cases of locally advanced non-small cell lung cancer treated initially with concomitant chemoradiotherapy and antiretroviral therapy. Both patients were male, ages 69 and 66, with known HIV infection and immunologically stable on antiretroviral therapy. Presenting symptoms included superior sulcus tumor with left arm immobility and sensory disturbance in case 1 and right lower bronchus constriction in case 2. Symptoms were controlled by chemoradiotherapy. Conclusion: These cases illustrate that intensive anticancer therapy administered to the HIV-infected population can be tolerated even though these patients seem to be too fragile for both chemotherapy and radiotherapy, especially since the potential benefit remains uncertain. Recent improvements in chemoradiotherapy and supportive care have enhanced tolerance for such therapy.

show abstract

Lung cancer, a new challenge in the HIV-infected population

Cited by 45 publications

References 71 publications

HIV-Associated Lung Cancer

HIV-Associated Lung Cancer

HIV Infection in the Etiology of Lung Cancer: Confounding, Causality, and Consequences

Concomitant Chemoradiotherapy and Antiretroviral Therapy for HIV-Infected Patients with Locoregionally Advanced Non-Small Cell Lung Cancer: Benefit and Tolerability of Treatment in 2 Cases

Contact Info

Product

Resources

About